Lipid nanoparticles and transcranial focused ultrasound enhance the delivery of SOD1 antisense oligonucleotides to murine brain
Files
(Published version)
Date
2025
Authors
Ediriweera, G.R.
Sivaram, A.J.
Cowin, G.
Brown, M.
McAlary, L.
Lum, J.S.
Fletcher, N.L.
Robinson, L.
Simpson, J.D.
Chen, L.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Journal of Controlled Release, 2025; 378:221-235
Statement of Responsibility
Gayathri R. Ediriweera, Amal J. Sivaram, Gary Cowin, Mikayla L. Brown, Luke McAlary, Jeremy S. Lum, Nicholas L. Fletcher, Liam Robinson, Joshua D. Simpson, Liyu Chen, Joanna M. Wasielewska, Ella Byrne, John W. Finnie, Jim Manavisi, Anthony R. White, Justin J. Yerbury, Kristofer J. Thurecht, Kara L. Vine
Conference Name
Abstract
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease with extremely limited therapeutic options. One key pathological feature of ALS is the abnormal accumulation of misfolded proteins within motor neurons. Hence, reducing the burden of misfolded protein has emerged as a promising therapeutic approach. Antisense oligonucleotides (ASOs) have the potential to effectively silence proteins with gain-offunction mutations, such as superoxide dismutase 1 (SOD1). However, ASO delivery to the central nervous system (CNS) is hindered by poor blood-brain barrier (BBB) penetration and the invasiveness of intrathecal administration. In the current study, we demonstrate effective systemic delivery of a next-generation SOD1 ASO (Tofersen) into the brain of wildtype and G93A-SOD1 transgenic C57BL/6 mice using calcium phosphate lipid nanoparticles (CaP lipid NPs). We show that transcranial focused ultrasound (FUS) with intravenously administered microbubbles can significantly enhance ASO-loaded nanoparticle delivery into the mouse brain. Magnetic resonance imaging (MRI) and immunohistological analysis showed reduced SOD1 expression in the FUS-exposed brain regions and increased motor neuron count in the spinal cord of treated mice suggesting decreased motor neuron degeneration. Importantly, the BBB opening was transient without evidence of structural changes, neuroinflammation or damage to the brain tissue, indicating that the treatment is well tolerated. Overall, our results highlight FUS-assisted nanoparticle delivery of ASOs as a promising non-invasive therapeutic strategy for the treatment of ALS and CNS diseases more broadly.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2024 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).